CORDIS
EU research results

CORDIS

English EN
K'Watch Glucose: A ground-breaking biometric wearable for painless, minimally invasive and blood-free glucose monitoring.

K'Watch Glucose: A ground-breaking biometric wearable for painless, minimally invasive and blood-free glucose monitoring.

Objective

Diabetes is a global burden expected to affect 642 million people by 2040. In Europe, this disease affects 60 million people and costs over €90 billion to our constraint healthcare system. Today a major part of diabetes management relies on the monitoring of blood glucose levels several times a day. Monitoring needs to be thorough, frequent and accurate, to prevent a persistent imbalance in glucose-insulin levels and the resulting life-threatening events. Although the lives of 70 million diabetes cases worldwide depends on glucose monitoring several times per day, 80% of them fail to stick to this crucial regimen. One main reason is the poor performance of self-monitoring devices. Most of the monitoring systems available today measure blood glucose, becoming painful and time-consuming, often incompatible with daily routines. Some of them adopt the form of a wearable, but devices and replacements are costly, bulky and very evident, giving raise to social stigma. It is evident that new monitoring systems are needed to enhance adherence to the necessary management procedures. In response, we at PKparis have developed, patented and validated K'Watch Glucose, a unique biometric wearable device in the shape of a smart watch that includes glucose monitoring among its many features. Hidden in the rear side of the watch, our biosensor measures glucose levels in the skin, in a minimally invasive manner and independently from blood. Our easy-to-use solution enables users to monitor glucose rapidly, anywhere, anytime and with no one noticing. Before reaching market maturity we need to finalise its development and business preparation. Thus, in Phase 1 we aim to run a Feasibility Study that helps us warrant all technical, commercial and financial standpoints of the project. Along the social and market impacts foreseen for K'Watch Glucose 5 years from launch, it will also boost our growth, expecting €71.77 million in profits, 100 new people and a ROI of 30.88 per euro invested.

Coordinator

PKVITALITY

Address

14 Avenue De L'Opera
75001 Paris

France

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 50 000

Project information

Grant agreement ID: 781100

  • Start date

    1 August 2017

  • End date

    30 November 2017

Funded under:

H2020-EU.2.1.1.

H2020-EU.2.3.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

PKVITALITY

France